You are here
Articles
Posted on Friday, October 1, 2021 - 10:40am
What is D*action?
Posted on Tuesday, September 7, 2021 - 3:24pm
Conclusions: In this first controlled study comparing treatments for resistant/intolerant (R/I) pts with CML, asciminib, a first-in-class STAMP inhibitor, demonstrated statistically significant and...
Posted on Tuesday, September 7, 2021 - 2:28pm
Chronic myeloid leukemia (CML) is a blood cancer. Unlike other cancers CML treatment is lifelong and many patients experience side effects.
Posted on Friday, September 3, 2021 - 2:34pm
Conclusions: These updated results continue to support 50 mg of dasatinib daily as an effective and safe dose for newly diagnosed early CML-CP.
Posted on Monday, August 23, 2021 - 1:48pm
MyeloidScan – Long COVID in patients with myeloid blood cancers
Have you had COVID 19 infection? We need to find out more about long covid affects people like you – can you help us?
Posted on Wednesday, June 30, 2021 - 11:54am
A British Society for Haematology Guideline on the diagnosis and management of CML
Posted on Wednesday, June 30, 2021 - 11:31am
Clinical trials show that tyrosine kinase inhibitor (TKI) treatment can be discontinued in selected patients with chronic myeloid leukaemia (CML).
Posted on Sunday, May 16, 2021 - 3:22pm
Simple Summary
Posted on Friday, May 14, 2021 - 10:54am
Abstract
Posted on Thursday, February 4, 2021 - 1:02pm
Haematologica. 2020 Dec 1; 105(12): 2738–2745.Published online 2020 Oct 9. doi: 10.3324/haematol.2019.242891
Posted on Tuesday, January 26, 2021 - 3:35pm
Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic...
Posted on Saturday, October 10, 2020 - 3:01pm
While the world eagerly awaits an effective vaccine, the current focus is on drug treatments.
Posted on Monday, August 31, 2020 - 5:49pm
In order to harmonize and standardize the management of patients with chronic myeloid leukemia (CML), the European LeukemiaNet (ELN) produced recommendations in the previous years.
Posted on Monday, August 31, 2020 - 5:39pm
Authors: Graeme Smith Jane Apperley Dragana Milojkovic Nicholas C. P.
Posted on Thursday, August 27, 2020 - 11:23am
Press Release
- ‹ previous
- 2 of 33
- next ›